Transcriptional regulator ERG (ERG) (ERG)

Transcriptional regulator ERG is a member of the ETS (E26 transformation-specific) family of transcription factors, playing essential roles in hematopoiesis, vascular development, and angiogenesis (UniProt P11308) [1]. It acts as a sequence-specific DNA-binding protein that regulates the expression of genes involved in cell proliferation, differentiation, and apoptosis. ERG is a significant proto-oncogene, most notably characterized by the TMPRSS2-ERG gene fusion found in approximately 50% of prostate cancer cases, which leads to aberrant, androgen-driven overexpression (Tomlins et al., 2005) [2]. This overexpression promotes oncogenic phenotypes including increased cell migration, invasion, and epithelial-to-mesenchymal transition (PubMed: 28235554) [3]. Beyond prostate cancer, ERG is involved in Ewing sarcoma through EWS-ERG chromosomal translocations and in various leukemias where its high expression is associated with poor clinical outcomes (NCBI Gene: 2078) [6]. Although transcription factors have historically been difficult to target, current therapeutic strategies focus on small molecules like VPC-18005 that disrupt ERG's DNA-binding activity or its interaction with co-activators, as well as experimental proteolysis-targeting chimeras (PROTACs) designed for its degradation [4, 5].

Other names

ETS-related genep55ERG-1ERG-2ERG-3Transcriptional regulator ERG

Inhibition of DNA binding to the ETS consensus sequence, disruption of protein-protein interactions with transcriptional co-activators (e.g., Androgen Receptor), and targeted protein degradation via PROTACs [3, 4].